Adding a free radical-scavenging nitrone moiety on tetramethylpyrazine, we have previously synthesized a chemical named 2-[[(1,1-dimethylethyl)oxidoimino]-methyl]-3,5,6-trimethylpyrazine (tetramethylpyrazine nitrone, or TBN) and proved its neuroprotective effect but with limited understanding of its mechanism. Here we ask if TBN protects retinal ganglion cells (RGCs) against excitotoxicity induced by NMDA and explore the underlying mechanism. NMDA was intravitreally injected to induce RGC injury in rats, followed by daily intraperitoneal administrations of TBN. Measurements of TBN concentration at different times after intraperitoneal administration showed that more than 200 lM TBN reached the aqueous humor quickly. Then RGCs' survival was evaluated by quantifying Brn3-positive cells, and retinal functions were examined by electroretinogram and visual behaviors. TBN significantly increased the survival of RGCs after NMDA insult, recovered the amplitude of photopic negative responses to flash, and restored the visual behavior. Furthermore, TBN inhibited the apoptotic process, as indicated by the elevated ratios of cleaved caspase-3/ caspase-3 and of Bax/Bcl-2, and decreased the level of reactive oxygen species. Moreover, TBN reduced RGC's calcium overload induced by NMDA or by KCl. Whole-cell patch recording from RGCs further showed that TBN slightly but significantly inhibited L-type calcium channels, but had little effect on T-type calcium channel or NMDA-, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid(AMPA)-induced current. Thus our data indicate that TBN alleviates NMDAelicited injury of rat RGCs both morphologically and functionally, possibly by inhibiting the L-type calcium channel thus reducing Ca 2+ overload and by directly scavenging free radicals. Therefore, TBN may be a novel candidate for treating excitotoxicity-related visual disorders such as glaucoma.
Overactivation of glutamate receptors in the central nervous system causes neuronal cell death. This glutamate-induced excitotoxicity acts primarily through N-methyl-D-aspartate (NMDA) receptors and is implicated in the pathological mechanisms of many neurological diseases such as Alzheimer's (Hynd et al. 2004 ), Parkinson's (Hallett and Standaert 2004; Olivares et al. 2012) , and some retinal diseases including diabetic retinopathy (Ambati et al. 1997) , retinal artery occlusion (Wakabayashi et al. 2006) , and glaucoma (Dreyer 1998; Seki and Lipton 2008) . In these diseases, excessive NMDA receptor activation triggers calcium influx and subsequently increases the release of reactive oxygen species (ROS) and cytochrome c, resulting in apoptotic cell death (Seki and Lipton 2008) . In the eye, intravitreal injection of NMDA elicits loss of retinal ganglion cells (RGCs) (Lam et al. 1999) , which can be significantly reversed by effectively blocking oxidative stress (Sakamoto et al. 2014) or calcium channels (Binda et al. 2016) . Therefore, decreasing ROS and/or calcium overload may offer a potential therapeutic tool for protecting neurons from excitotoxicity.
An interesting molecule that seems to accomplish both tasks is 2,3,5,6-tetramethylpyrazine (TMP). TMP is the main active component of Ligusticum wallichii Franchat that has been used to treat ischemic stroke for centuries in China (Chen and Chen 1992) . In animal transient or permanent stroke models, TMP preserves the structural and functional integrity of mitochondria (Li et al. 2010) , reduces cellular inflammatory responses (Kao et al. 2013) , inhibits neutrophil activation (Chang et al. 2015) and thereby significantly reduces brain infarction volumes (Zhu et al. 2009 ) and improves neurological function recovery (Hu et al. 2013) . These actions are thought to be mediated by TMP's antioxidant properties (Cheng et al. 2007 ) and its ability to block certain voltage-gated calcium channels (Zou et al. 2001) . To further improve TMP's protection's action, we previously added to it a powerful free radical-scavenging nitrone moiety (Fig. 1a) to make a new chemical, 2-[[(1,1-dimethylethyl) oxidoimino]-methyl]-3,5,6-trimethylpyrazine (TBN). The derived molecule, TBN, exhibits stronger antioxidative activity than TMP and shows significant therapeutic effects in stroke models (Sun et al. 2008) (Zhang et al. 2016c) and in traumatic brain injury model (Zhang et al. 2016b) . Recently, TBN has entered a phase I clinical trial to treat ischemia in China (CFDA approval No. 2016L03629) . With its multifunctional potential of neuroprotection, TBN may offer a novel agent also for protecting neurons against excitotoxicity in neurological diseases.
However, so far, neither TBN's potential protective effect on neurotoxicity, nor its effect on calcium flux has been studied. Here we used the NMDA-induced excitotoxicity in retina as a model to test its effect on this type of injuries, and we further explored its action mechanisms. We hypothesize that TBN may protect RGCs against NMDA-induced injury by scavenging free radicals and inhibiting calcium overload. Indeed, we demonstrate that TBN protects RGCs in an NMDA-induced injury model both morphologically and functionally. Mechanistically we show that TBN: (1) reduces ROS level; (2) reduces Ca 2+ response to NMDA; and (3) inhibits the L-type calcium channel on RGCs. Thus our data support a dual action of TBN on RGCs.
Methods

Materials
The following materials and reagents, listed with their suppliers, were used in this study: TBN (Shanghai Medicilon Inc, Shanghai, China, Lot number: 20101002); memantine, NMDA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) (Sigma, Shanghai, China); for immunostaining: anti-Brn3 Santa Intravitreal injection of NMDA Animals were anesthetized with intraperitoneal (i.p.) injection of chloral hydrate (0.38 mg/g body weight), and pupils were dilated with phenylephrine hydrochloride and tropicamide drops. For most experiments, intravitreal injections were performed on one eye, but the behavioral test required bilateral injection. A needle that connected to a 50 lL micro-syringe was inserted approximately 1 mm behind the dorsal corneal limbus. Then 1 lL of 40 mM (equivalent to 40 nmol) NMDA dissolved in saline was injected into the vitreous to cause injury as previously described by Zhang et al. (2016a) and proved by our preliminary test. For sham group, saline alone was injected. The needle was kept in the vitreous for 10 extra seconds and was then slowly pulled out, and a drop of antibiotic gel was applied to the eye. Animals that developed cataracts or inflammation (9 out of 56 tested) were excluded from behavior and electroretinogram (ERG) study. Experiments were carried out using the protocol shown in Fig. 1(c) .
Drug administration
Starting on the day of NMDA injection, we i.p. injected rats daily for 5 days with different concentrations of TBN (25, 50, or 100 mg/ kg body weight). Because memantine is a non-specific NMDA receptor antagonist (Bormann 1989) , we i.p. injected memantine (10 mg/kg, as described by WoldeMussie et al. 2002) as a positive control of treatment. For the non-treated group, we injected normal saline. In another batch of experiments, we i.p. injected rats with TBN daily for either 1, 3, or 5 days (50 mg/kg body weight), and then killed them to check RGCs survival.
Measurement of TBN concentration in aqueous humor
To determine if TBN reaches the eye, we used high-performance liquid chromatography (HPLC) and measured the concentration of TBN in the rats' aqueous humor. Briefly, 5, 15, 30, 45, 60, 90, 180, 240 , and 260 min after i.p. injection of TBN (50 mg/kg body weight), the animals were anesthetized with sodium pentobarbital (40 mg/kg, i.p.) and the bilateral aqueous humor was extracted with a 1 mL syringe. Proteins in the aqueous humor were precipitated by adding methanol and acetonitrile (1 : 1 : 1, v : v : v). After centrifugation (12 000 g, 10 min), 20 lL supernatant was analyzed by an Agilent 1260 series HPLC system equipped with a UV detector (Agilent Technologies, Santa Clara, CA, USA). Chromatographic separation was performed on a Luna C18 column 250 9 4 mm, 5 lm, Phenomenex, Torrance, CA, USA). The mobile phase consisted of methanol and water (45 : 55, v/v) and was delivered at a flow rate of 1.0 mL/min. Chromatograms were monitored at a wavelength of 330 nm and the temperature of the column was kept at 35°C.
Visual behavior test
The visual behavior test was conducted on the 4th day after NMDA injection in both eyes using a dark-light box (custom-made by Metronet Technology Ltd, Hongkong) (Fig. 3c) . The box consisted of a dark chamber (30 9 50 9 50 cm, illuminated with infrared light) and a larger white chamber (50 9 50 9 50 cm, illuminated with bright white light). An aperture (10 9 12 cm) between the dark and light chambers allowed rats to travel freely from one chamber to the other. Two cameras, one installed in each chamber, captured the rats' activities and connected to a Noldus recorder and monitor. At the start of the trial, rats were placed in the middle of the light chamber; after 5 min, they were removed from the box. The time they spent in the dark chamber was summed by the Noldus EthoVision XT 8.0 software (Noldus, Wageningen, The Netherlands).
Electroretinogram
After the behavioral test, animals were dark adapted for 12 h at night, and ERGs were recorded the next day using the protocols described previously . Briefly, rats were anesthetized with chloral hydrate (0.38 mg/g body weight) under dim red light. The pupils were dilated by topical application of phenylephrine HCl (0.5%) and tropicamide (0.5%), and the eyes were lubricated and hydrated with 1% methylcellulose. Animals were placed on a heated platform and ERGs were recorded with gold plated wire loop electrodes contacting the corneal surface as the active electrodes. Stainless steel needle electrodes were inserted into the skin near the eye and into the tail, serving as reference and ground leads, respectively. For photopic ERGs, animals were light adapted for 5 min with bright green background (25 cds/m 2 ), and photopic responses to green flashes of 10.0 cds/m 2 were recorded using a Ganzfeld of a Roland RETI-scan system (Roland Consult, Brandenburg, Germany). ERG data were collected through the amplifier of the RETI-scan system at a sampling rate of 2 kHz. Animals that failed to give clear light responses of b-wave were excluded. ERG waveforms were analyzed with RETIport software (Roland Consult, Brandenburg an der Havel, Germany) after applying 50 Hz low-pass filtering. For photopic negative responses (PhNR), the amplitude of the negative peak following the b-wave (the first positive peak in the ERG trace) was measured relative to the baseline.
Tissue processing and immunohistochemistry of RGCs Animals were killed by anesthetic overdose and the eyes were enucleated. Whole-mount retinas were fixed in 4% paraformaldehyde in 0.01 M phosphate-buffered saline for 60 min. They were washed and placed in 0.01 M phosphate-buffered saline containing 5% normal donkey serum with 3% Trition-X-100 for 1 h, and then incubated in goat-anti-Brn3 (marker of RGCs) antibody (1 : 100) or Brn3a (1 : 200) for 2 days at 4°C. After thorough washes, retinas were incubated with donkey-anti-goat IgG secondary antibody (1 : 1000) for 3 h at 25°C. Retinas were flat-mounted on glass slides and cover-slipped for examination.
Sampling and counting RGCs
Survival of RGCs was assessed by counting the number of Brn3-positive cells (or Brn3a-positive cells in Figure S1 ) in the flat wholemount retina under a fluorescent microscope (Leica 6100B, Leica Camera, Wetzlar, Germany). For each retina, we acquired about 30 images (641 9 479 lm) that were separated by 1.5 mm and covered the whole retina. The number of Brn3-positive cells was summed from all images using the cell counter of the Image J software program (NIH, Bethesda, Maryland, USA), and was then averaged and divided by the area to get the density value for one retina. The cell counting was performed by an independent analyzer. The data from all retinas of each group were then averaged.
Western blot analysis
Retinas from control or treated eyes were homogenized and lysed for 30 min. After centrifugation, the concentration of soluble protein was determined using a bicinchoninic acid assay kit (Beyotime, Shanghai, China). 40 lg of retinal protein per lane was loaded and separated electrophoretically on a 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel, and then was transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). Membranes were incubated in primary antibodies (1 : 1000) overnight at 4°C. Following wash, they were incubated in the secondary antibody (1 : 6000) for 2 h at 25°C then washed. Immuno-positive bands were revealed with enhanced chemoluminescence (Millipore). Image processing and semiquantification were performed with Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA). Measurements were repeated at least four times for each experiment.
Detection of ROS production
We detected ROS production 6 h after NMDA application, by which time all RGCs showed pyknotic nuclei (Li et al. 2002) and TUNEL-positive cells were evident in the ganglion cell layer (Manabe and Lipton 2003) . At the same time rats were i.p. injected with TBN (50 mg/kg body weight), memantine (10 mg/kg body weight), or normal saline. Four hours later, rats were injected intravitreally with 1 lL 50 lM CellROX Green Reagent. Two hours after injection, rats were anesthetized and the eyes enucleated and fixed in 4% paraformaldehyde for 1 h on ice. Eyes were then processed with increasing concentrations of sucrose and frozen in Tissue-Tek OCT compound (Sakura Finetechnical, Tokyo, Japan).
Retinas were cryo-sectioned through the optic disk longitudinally at a thickness of 15 lm, and sections were mounted in Vectashield. Fluorescent images were obtained using a Leica fluorescent microscope. For counting CellROX-positive cells at the same eccentricity in each slice, we imaged two regions at around 1/3 of the retinal radius (1.0-1.6 mm) from the center of optic disk (one on each sides). The number across all slices (around 30-60 slices) from each retina was averaged to provide one data point, then the data from all retinas were averaged for each group.
Calcium imaging
Calcium imaging was performed on retinas of untreated animals. To enable retrograde labeling of RGCs, following enucleation, Fluo-4 pentapotassium salt (0.5 lL of 40 mM stock in H 2 O) was injected into the optic nerve stump approximately 1 mm posterior to the globe (Sargoy et al. 2014a ). An eyeball was placed in Ringer solution bubbled with 95% O 2 /5% CO 2 for 1 h at 5°C in the dark. The retina was then isolated and mounted on a black filter paper (Millipore) and placed in a perfusion solution containing (in mM): 120 NaCl, 3 KCl, 2 CaCl 2 , 1.20 NaH 2 PO4, 1 MgCl 2 , 25 NaHCO 3 , and 10 glucose, bubbled with 95% O 2 /5% CO 2 . NMDA (500 lM) was applied to elicit calcium influx.
Images were acquired at 20 s intervals with a Zeiss two-photon scanning microscope equipped with a water-immersion 209 Axoplan 406 (NA 0.8) objective (Zeiss, Oberkochen, Germany). Excitation was provided by the 488 nm line of the argon laser while collecting emission through a 505 nm long-pass filter. Fluorescent intensity values were acquired by placing regions of interest on RGCs somas that responded to NMDA application, and then analyzing with Image J Plus.
To induce calcium overload with high KCl, retinas were perfused 2 min in a solution contained (in mM): 68 NaCl, 60 KCl, 1.25 NaH 2 PO 4 , 25 NaHCO 3 , 1 MgCl 2 , 2CaCl 2 , 12glucose. Retinas were then washed for 10 min, treated with 300 lM TBN for 10 min, and tested again for responses to high KCl. Retinas were then washed for 20 min, and tested again with high KCl. Segments of axons with obvious calcium were chosen for the analysis. For each segment, the maximum intensities of KCl-induced fluorescence before, right after the treatment of TBN, and after wash were normalized to the response before TBN treatment, and the ratios were averaged and compared to the value before TBN treatment.
Whole-cell recording Whole-cell recordings were performed on RGCs from whole-mount retina flattened on a membrane filter. The tissue was transferred into a recording chamber and perfused with oxygenated (95% O 2 , 5% CO 2 ) bath solution (mM: 125 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 25 NaHCO 3 , 2 CaCl 2 , 15 glucose, 1 MgCl 2 with pH adjusted to 7.2-7.4 with NaOH) maintained at~34°C with a flow rate of 1-2 mL/min.
Under Nikon microscope using differential interference contrast (DIC) lens, a ganglion cell with a large soma (> 20 lm diameter) was selected for recording. Whole-cell membrane current was recorded with a glass pipette (tip resistance: 8-10MΩ) containing the following (in mM): 120 CsCH 3 SO 4 , 12 Creatine, 10 TEA-Cl, 10 HEPES, 4 MgCl 2 , 4 ATP, 1 EGTA, with pH adjusted to 7.2-7.4 with CsOH and osmolality 290 mOsmol.
In experiments testing the NMDA-or AMPA-induced current, GABA A , Glycine receptors, and voltage-gated sodium channels were blocked by bicuculline (10 lM), strychnine (10 lM), and tetrodotoxin (0.1 lM) that was added to the bath solution. To record NMDA-induced current, MgCl 2 was removed and 5 lM glycine was added in the bath solution (Zhang et al. 2011) , the AMPA receptors were blocked by 10 lM 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f] quinoxaline-2,3-dione. To record AMPA-induced current, NMDA receptors were blocked with 10 lM AP-5. For local application, 500 lM NMDA or AMPA was puffed onto dendrites of the recorded ganglion cell with a puffing pipette that used positive pressure (2-4 psi) via a computer-controlled solenoid valve (Picrosprizer; General Valve, Fairfield, NJ, USA).
Data were collected using Pulsefit 8.0 (HEKA Elektronik, Lambrecht, Germany) with a HEKA amplifier at a sample rate of 5 kHz, filtered at 2 KHz. Data were analyzed using Patchmaster (HEKA) and Igor 5.2 (WaveMetrics, Lake Oswego, OR, USA). Unless stated otherwise, cells were clamped at À70 mV. All chemicals were obtained from Sigma.
Statistical analysis
All data were analyzed with GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA) and are presented as mean AE SEM. Statistical comparisons were made using two-tailed Student's t-tests when comparing two groups or one-way ANOVA tests followed by post hoc multiple comparison when comparing more than two groups. p values < 0.05 were considered statistically significant and p values < 0.01 were considered highly significant. Sample size was determined based on previous experiments in the field (Yamamoto et al. 2014; Zheng et al. 2015; Zhang et al. 2016a ) and detailed in Table S1 and Figure S2 .
Results
TBN quickly enters the aqueous humor after i.p. injection To determine if TBN injected i.p. can present in the eye, we measured TBN concentration using HPLC of the aqueous humor extracted at different times after i.p. injection. TBN was already detectable in the aqueous humor 10 min after injecting 50 mg/kg, and its concentration was 84 AE 14 lM. This concentration reached its peak of 266 AE 8 lM 45 min after injection, dropped to about half 180 min after injection, and dropped to 21 AE 2 lM about 360 min after injection (Fig. 1b, n = 3) . The concentration of TBN we detected was well in the range of the reported effective concentrations of TBN in vitro (50-500 lM) (Guo et al. 2014) . Thus TBN is present in the eye for a substantial length of time, and can influence biological processes.
TBN increases RGC survival after NMDA injury
To test TBN's potential protective effect on RGCs, we estimated their survival by staining retinas with an antibody against Brn3, a RGC marker (Jain et al. 2012) . Five days after administering NMDA, the number of Brn3-positive cells significantly decreased (n = 8), dropping to 24% of the number seen in the sham (without NMDA injury, n = 4) group (Fig. 2a, b , and f; p < 0.01). To determine if TBN could rescue the RGCs at all, we first administered 100 mg/kg of TBN (as reported before by Sun et al. 2012) and measured the percentages of surviving RGCs. With 100 mg/kg of TBN, RGC survival rose to over 40% of the sham level, significantly higher than the level of the non-treated group ( Fig. 2d and f ; n = 9, p < 0.01). A similar increase in survival was achieved with memantine ( Fig. 2c and f , n = 7). To test for possible TBN toxicity, we applied TBN (100 mg/kg) to the sham group and found no change (Fig. 2e, n = 5) , thus indicating that TBN at the used concentrations is safe.
We next examined the dose-dependent protective effect of TBN by administering it at different concentrations after NMDA injury (Fig. 2g) . Injecting 25 mg/kg (n = 6) did not increase RGC survival, but injecting 50 (n = 14) and 100 (n = 14) mg/kg greatly increased it (p < 0.05, one-way ANOVA-test). Thus, for the following experiments, we primarily used 50 mg/kg TBN, but occasionally tested also the 100 mg/kg concentration.
We further tested whether TBN can protect RGCs at an earlier stage after NMDA injection. We found that the survival rate of RGCs significantly decreased from day 1 to day 5, but this survival was always greater with TBN treatment (supplemental Fig. 1 ).
TBN enhances the inner retinal function after NMDA injury
To determine whether surviving RGCs respond to light, we tested RGC field potentials using the ERG PhNR. The ERG PhNR is a negative wave that appears under light-adapted conditions (photopic) after the photopic b-wave (Fig. 3a) . Since its amplitude decreases in glaucoma patients and rodent models with injury in RGCs, it is thought to represent the RGC light response in addition to activities in amacrine cells and surrounding glia in the inner retina (Viswanathan et al. 2001; Li et al. 2005; Chrysostomou and Crowston 2013) . At flash intensities of 10.0 cds/m 2 , NMDA application significantly decreased the PhNR amplitude to 36% of the sham group amplitude (n = 12, p < 0.01), whereas the addition of TBN (50 mg/kg, n = 12) and memantine (n = 9) significantly increased the PhNR amplitude to 97% and 101% of the sham level, respectively, displaying a highly significant change from the non-treated group (n = 12, p < 0.01) (Fig. 3b) . Thus TBN protects the inner retina not only morphologically but also functionally.
TBN improves visual behavior of rats after NMDA injury
To further examine this protection of RGC function, we tested it behaviorally by estimating the tendency of rats to stay in the darkness. With normal vision, rats prefer to stay in the dark area, whereas with damaged vision, they lost the ability to discriminate illuminance and spend about equal time in the dark and light areas (Zhang et al. 2016a) . A sham-operated rat, when placed in the center of a lighted chamber, entered the dark chamber and spent most of its time there (example movement trace shown in Fig. 3c ).
After NMDA injection, the time that rats remained in the dark chamber decreased to 71% of the sham time (n = 12, p < 0.01). TBN application extended this time to 94% of the sham level, with a significant difference between 50 mg/kg TBN-treated (n = 12) and non-treated groups (n = 12, p < 0.05). Memantine showed similar behavioral improvements (n = 11, p = 0.06 compared to non-treated group) (Fig. 3d) .
TBN inhibits NMDA-induced apoptosis
So far our data indicate that TBN protects RGCs against NMDA-induced injury both structurally and functionally. To explore the mechanism of this neuroprotection, we first tested whether TBN inhibits the NMDA-induced apoptosis, and then tested how well it scavenges free radicals and blocks calcium overload in RGCs.
Since NMDA is known to continue to induce apoptosis in the ganglion cell layer even several days after injection (Lambuk et al. 2017) , we explored whether TBN inhibits these apoptotic processes 5 days after NMDA injection. We tested the expression of the pro-apoptotic proteins Bax and cleaved caspase-3 and that of the anti-apototic factor Bcl-2 because they were shown to be affected by NMDA (Zheng et al. 2015) . Compared to sham retinas, the expression levels of cleaved caspase-3 and Bax increased substantially after NMDA injury (for cleaved caspase-3,~14-fold of sham, p < 0.01; for Bax,~2-fold of sham, p < 0.05), whereas that of total caspase-3 and of anti-apoptotic protein Bcl-2 changed very little (Fig. 4a) . In accordance, the ratios of (cleaved caspase3)/(caspase-3) increased to 15-fold and that of Bax/Bcl-2 increased by 2-fold of sham (p < 0.05), confirming activation of the apoptosis processes ( Fig. 4b  and c) . Interestingly, we found that administering 50 mg/kg TBN decreased these ratios significantly when compared to the non-treated group (p < 0.05). A similar trend was seen with 100 mg/kg TBN or memantin. Thus TBN inhibits NMDA-induced apoptosis in retina.
TBN decreases NMDA-induced free radicals NMDA injection is known to induce oxidative stress (Gyengesi et al. 2012 ) and anti-oxidative stress agents rescue RGCs from NMDA-induced injury (Drahota et al. 2012) . Using cell-free assay (Sun et al. 2012) or SH-SY5Y cells (Marin et al. 1993) , TBN was shown to decrease oxidative stress. Thus, we tested whether TBN releases this oxidative stress in vivo. Since ROS, including free radicals such as superoxide anions and hydroxyl radicals, are one of the main contributors to oxidative stress, we evaluated this level by measuring ROS production in the ganglion cell layer (GCL) within 6 h after NMDA application, when the apoptotic peak happens. We labeled retinas with CellROX (Yamamoto et al. 2014) , which accumulates in mitochondria and nuclei and labels the location of ROS production. NMDA injection produced numerous CellROX-positive cells in all nuclear layers (Fig. 5a, Left) , but the major effect was on cells located in the GCL (arrows). Six hours after NMDA injection (n = 8), the number of CellROX-positive cells in the GCL layer was increased to 5 times of the sham group (n = 8, p < 0.01); TBN (50 mg/kg) (n = 7) or memantine (n = 7) decreased this number back to the sham level (p < 0.01, Fig. 5a and b) . Thus TBN drastically decreases NMDA-induced ROS (or free radicals) in ganglion cells and probably also amacrine cells.
TBN reduces NMDA-induced calcium increase in RGCs
Since NMDA activates a variety of glutamate receptors and evokes calcium influx that in turn increases ROS and excitotoxicity (Sucher et al. 1997) , we tested whether TBN affects calcium overload, as shown in cultured SH-SY5Y cells (Sun et al. 2012) . We labeled RGCs with the calcium indicator Fluo-4 by retrograde labeling, and imaged wholemount retina to monitor their fluorescent signal over time (Fig. 5c ). Superfusing 500 lM NMDA for 2 min elicited bright fluorescence signals in many RGCs, confirming the reported increase in intracellular [Ca 2+ ] levels by NMDA. After washout, we incubated the retina for 10 min either in the perfusion buffer alone (control group), in buffer + 300 lM TBN, or buffer + 100 lM memantine, and then re-tested the responses to NMDA. Since there are large variations among the fluorescent signals across cells and tissues, fluorescent signals of the same cell were monitored and compared.
In the control group, the 2nd NMDA-evoked calcium fluorescence was only slightly lower than the first (90 AE 8%, n = 12, Fig. 5 c and d, lower trace) . In contrast, in TBNtreated cells, the 2nd response was 78 AE 4% of the 1st one (n = 8) (Fig. 5d upper trace) . The ratio of the 2nd to the 1st NMDA-elicited calcium rise after TBN treatment was significantly smaller than that ratio for control (p < 0.05, Fig. 5e ), indicating that TBN can reduce the NMDA-induced calcium increase in RGCs. Memantine showed a similar effect with the 2nd response dropping to 76 AE 5% of the 1st one (n = 8, p < 0.05 compared to control). Thus our data indicate that TBN suppresses the NMDA-induced calcium overload. TBN effect may be direct by blocking the NMDA receptors, or indirect by inhibiting downstream events.
TBN does not affect NMDA-or AMPA-induced current in RGCs To explore how TBN decrease calcium overload in RGCs after NMDA application, we next recorded from single RGCs and compared their responses to local puff of NMDA or AMPA before and after perfusing TBN for 10 min (an example of a recorded cell with the recording and puffing pipette is shown in Fig. 6a ). For these experiments, GABA A , glycine receptors, voltage-gated sodium channels and AMPA receptors were blocked by adding bicuculline (10 lM), strychnine (10 lM), and tetrodotoxin (0.1 lM) in the bath solution. Local application of NMDA onto the dendrites induced a large inward current for a few seconds (Fig. 6b-d) , and this response was totally diminished by 50 lM AP-5 (data not shown), confirming the specificity of NMDAinduced current. Perfusion of 50 lM memantine also greatly decreased the NMDA-induced current to 45 AE 7% of the original amplitude (Fig. 6c , n = 3, p < 0.05). In contrast, TBN had little effect on the NMDA-induced current. (Fig. 6d, 104 AE 23%, n = 3). Similarly, TBN had little effect on the amplitude of AMPA-induced current (Fig. 6f-h , 104 AE 9% of the original amplitude, n = 3). Thus our data indicate that TBN does not block NMDA or AMPA receptors directly in RGCs.
TBN inhibits L-type calcium channels but not T-type in RGCs
As NMDA application may indirectly activate voltage-gated calcium channels by depolarizing the cell thus inducing calcium overload (Hartwick et al. 2008) , we next explored whether TBN may affect L-type or T-type voltage-gated calcium channels, known to be functional in RGCs (Karschin and Lipton 1989) . The L-type channel was activated by a voltage clamp jump from À40 mV for 50 ms to 0 mV for 100 ms. This gave an average of 541 AE 101 pA. Following application of TBN-containing bath solution (for 10 min), the voltage jump produced smaller current that averaged at 440 AE 94 pA (80 AE 2.5% of the initial control current, p < 0.05, paired t-test) ( Fig. 7a and c, n = 3, p < 0.05). After the wash (for 10 min), the current was restored to 502 AE 105 pA (92 AE 3.1% of the control). The T-type channel was activated by jumping the clamped voltage from À80 mV for 50 ms to À20 mV for 200 ms. This produced an average of 671 AE 145 pA. Application of TBN did not affect the amplitude of this current (668 AE 152 pA, or 98 AE 2.8% of the control, Fig. 7b and c, n = 4). Thus our data suggest that in RGCs, TBN inhibits L-type calcium channels but not T-type.
To further test the global effect of TBN on the L-type calcium channels of RGCs, we imaged the calcium signal from the axons of ganglion cells, where only L-type calcium channels are found (Sargoy et al. 2014b) . Perfusing 60 mM KCl increased the fluorescence signals in many axons of RGCs ( Fig. 7d and e) ; and this rise was slightly but significantly reduced by TBN to 86 AE 4.4% of initial control response (p < 0.05, n = 6). After washout, the responses to KCl application completely recovered (103 AE 4.1% of the control, Fig. 7f ). Thus our calcium imaging data further support the notion that TBN reduces calcium overload by inhibiting the L-type calcium channel.
Discussion
In this study, we investigated the neuroprotective effects of TBN, a derivative of TMP, on RGCs in vivo. We demonstrated that TBN significantly decreases the following destructive effects of NMDA: (i) loss of RGCs; (ii) decrease in ERG response; (iii) impairment of visual behavior; (iv) increase in apoptotic-related proteins; (v) increase in ROS level; and (vi) calcium overload. Furthermore, we found that TBN inhibits the L-type calcium channels but not the T-type calcium channels, the NMDA-, or the AMPA-induced current. To our knowledge, this is the first study that discloses TBN's mechanism of blocking calcium overload and shows TBN's potential to treat excitotoxicity visual diseases.
Morphological versus functional neuroprotective effect of TBN In our experiments, NMDA-induced injury left only~24% of the RGCs intact, and TBN treatment raised this percentage to over 40%. Interestingly, our functional test revealed a greater recovery where the amplitude of the PhNR response increased from~30% in the untreated group to almost 100% in TBN-treated animals. Since PhNR represents a compound potential, such recovery may occur by contributions from other cells, particularly amacrine cells. Similarly large improvement of PhNR and modest in RGCs survival also occurred when Lutein was used to protect from NMDA injury (Zhang et al. 2016a) . Our behavioral results constitute further evidence of the greater functional rescue, which showed an almost normal preference to dark corners after TBN treatment. Thus our data indicate that the morphological protective effects of TBN translate into functional improvement. Moreover, this data suggest that a small percentage of protected RGCs is sufficient to maintain or restore important visual functions. A similar phenomenon is seen when restoring vision by transfecting photosensitive proteins into RGCs of photoreceptor-degenerated animals: transfection of only~7% of RGCs with melanopsin restores the basic visual behavior of rd1 mice (Lin et al. 2008) . Given that a small number of RGCs can mediate a substantial visually mediated behavior, it appears that even a moderate protection or delay of RGCs death will benefit patients suffering from glaucoma, thus justifying testing neuroprotective agents.
Mechanisms of TBN neuroprotection
A large volume of studies suggest that NMDA injury results from cytotoxic processes related to calcium overload, increases in ROS production and increase in pro-apoptocic proteins (Peng and Jou 2010) . In retina, the NMDA-induced RGCs cell death is attributable either to a direct effect of calcium overload in RGCs, or an indirect effect through Muller cells.
Here we tested several elements that are involved in apoptosis. First, we found that TBN-treated retinas produced much less ROS than the non-treated retinas. Since TBN is a potent anti-oxidant (as proven by biochemical experiments) that scavenges free radicals including hydroxyl (ÁOH), superoxide (O 2 À ), and peroxynitrite (ONOO À ) (Sun et al. 2012) ; its strong reduction in ROS level in retina can be expected. TBN's ability to alleviate oxidative stress damage was also demonstrated by our recent research in a rat model of traumatic brain injury (Zhang et al. 2016b ). However, with almost normal ROS level after TBN treatment, the survival of RGCs was still modest, suggesting that antioxidation is not sufficient to fully protect the RGCs. Other apoptotic events may be in action and independent of ROS production. Then we asked if TBN has an effect on anti-and proapoptotic events later in the process. We found that indeed two pro-apoptotic proteins, cleaved caspase-3, and Bax, shown by us and others to be up-regulated by NMDA injury (Lv et al. 2016) , are reduced with TBN treatment. Similarly, TBN prevents the down-regulation of Bcl-2, caspase-3 and the up-regulation of Bax caused by traumatic brain injury in rat (Zhang et al. 2016b) .
Finally, with regards to the effects of NMDA-induced calcium influx, it has been shown previously that memantine, an NMDA antagonist, greatly reduces the number of dying RGCs (Hare et al. 2001) . In our hands the effect of TBN on cell death was similar to that of memantine, so we tested whether TBN reduces intracellular calcium in retinal cells and whether it can block certain calcium permeable channels (NMDA receptor, AMPA receptor, and L-and Ttypes voltage-activated channels). Our calcium imaging data showed that indeed TBN treatment decreases NMDAinduced calcium elevation in cells of the ganglion cell layer. However, this effect was not mediated directly by blocking the NMDA or the AMPA receptor, since patch clamp recording showed that the current passing through these channels is unchanged by TBN. Instead, TBN decreased the L-type calcium current. This action is consistent with the knowledge that the parent compound of TBN is TMP, a compound that has been shown to block L-type calcium channel (Zou et al. 2001; Ren et al. 2012) . Further evidence for the inference that TBN protects RGCs via reducing calcium overload comes from our results showing that high KCl-induced calcium overload in RGC axons, where the majority of calcium channels are L-type potassium channels (Sargoy et al. 2014b) , was also reduced by application of TBN. These results are also consistent with our previous report that TBN significantly reduces Ca 2+ entry into cultured SH-SY5Y cells induced by KCl (Sun et al. 2012) .
Therefore, we conclude that a main pathway for TBN neuroprotective effect is mediated via blocking the L-type Ca 2+ channels. This would fit with all hypotheses regarding NMDA injury since these channels would be activated whenever RGCs depolarize, whether directly by NMDA receptors located on RGCs, or indirectly through NF-kB to tumor necrosis factor (TNFa) pathway in Muller cells which increases AMPA-mediated currents in RGCs (Lebrun-Julien et al. 2009 ). However, it is currently not possible to know whether the protective action of TBN is only the result of reducing calcium influx to RGCs, in which the reduction in ROS and pro-apoptotic proteins would be consequential to reducing calcium overload, or whether TBN has a dual action by also reducing ROS directly. It has been shown that in primary cultures of rat RGCs lacking antioxidant in the medium, RGCs die at a greater rate than in medium including them (Ozawa et al. 2013) . Thus, an independent action on ROS is not only feasible, but also likely given the antioxidant properties of TBN.
Potential of TBN to treat retinal disease
The significant protective effect of TBN on RGCs both morphologically and functionally suggests a potential application for treating retinal diseases involving excitotoxicity, such as diabetic retinopathy (Ambati et al. 1997) , retinal artery occlusion (Wakabayashi et al. 2006) , and glaucoma. Along with its dual function of blocking calcium overload and scavenging free radicals as shown in the present and previous studies (Sun et al. 2012; Guo et al. 2014) , TBN also retains the ability of its parent TMP to lysis blood clots, and reduce neuroinflammation (Guo et al. 2014) . Thus unlike memantine that failed the phase III clinical trial (Osborne 2009 ) to treat glaucoma, TBN may offer advantages by targeting multiple pathological pathways simultaneously.
With its ability to penetrate the blood-brain barrier or blood-retina barrier, TBN can quickly reach the target area by i.p. injection (shown here and in Sun et al. 2012 ). Although we tested TBN's effect after i.p. injection, it would be better to administer it orally or with topical drops. Oral administration is likely to succeed since it was effective in treating Parkinson's disease rat models (Guo et al. 2014) ; however, the kinetics of TBN in aqueous humor after oral administration must first be determined. Topical application is a more attractive option, but since TBN is not stable in solution for more than 5 h, it must be supplied as a dry powder for dissolving in solution and must be disposed of after each use. This method would again first require testing the kinetics of TBN in aqueous humor after corneal administration.
In conclusion, TBN protects RGCs both morphologically and functionally, potentially by scavenging free radicals and preventing calcium overload. With these dual properties, as well as the ability to block L-type calcium channels, TBN, a drug already in clinical trial to treat ischemia stroke, may serve as a potential chemical to treat excitotoxicity diseases in retina as well as in central nervous system.
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